Antibodies Binding KIT D4 Domain for Leukemia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for KIT-associated disorders, such as certain cancers, are limited by the inability to effectively target and inhibit the abnormal activity of the KIT receptor tyrosine kinase, particularly at its D4 domain, which is involved in constitutive activation in cancer cells.
Innovation Solution
Development of antibodies and antigen-binding fragments that specifically bind to the D4 domain of the KIT receptor, inhibiting its activity, along with conjugates and pharmaceutical compositions for therapeutic use, including expression in CHO cells and use in diagnostic methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for KIT-associated disorders, then treatment coverage is limited, but the ability to effectively target and inhibit abnormal KIT activity is insufficient
Solution Approach 1:
The antibody targets a specific segment (D4 domain) of the KIT receptor rather than the entire receptor, enabling precise inhibition of abnormal KIT activity while preserving other functions. This segment-specific approach resolves the contradiction by providing both effective targeting (improving versatility) and reliable inhibition (improving effectiveness).
Solution Approach 2:
The invention applies local quality by designing an antibody that specifically binds to the D4 domain with unique properties (high affinity, non-immunogenicity) rather than treating the entire KIT receptor uniformly. This localized approach allows effective inhibition of pathological activity while maintaining adaptability to different KIT-associated disorders.
2Reliability
If antibodies are developed to specifically bind KIT D4 domain, then KIT activity inhibition is improved, but production complexity increases
Solution Approach 1:
The antibody design incorporates self-service principles by using humanized sequences that reduce immunogenicity, allowing the product to serve itself by minimizing immune system rejection without requiring complex immunosuppression protocols. This resolves the contradiction by maintaining high inhibition reliability while simplifying production and clinical use.
Solution Approach 2:
The invention changes key parameters of the antibody structure (humanized sequences, specific CDR regions) to achieve both high KIT binding affinity and low immunogenicity. These parameter changes enable effective KIT inhibition while simplifying production processes and reducing clinical complexity.
3Measurement precision
If high specificity binding to KIT D4 is achieved, then therapeutic precision is improved, but manufacturing cost increases
Solution Approach 1:
The humanized antibody design allows for cost-effective manufacturing by reducing the need for complex purification and stabilization processes. The simplified structure enables production using standard biotechnological platforms, resolving the contradiction between high binding specificity and manufacturing ease.
Data Source
AI summary
Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-associated disorder or disease and methods of diagnosing a KIT-associated disorder or disease using the antibodies described herein.